Assenagon Asset Management S.A. Grows Stock Holdings in USANA Health Sciences, Inc. (NYSE:USNA)

Assenagon Asset Management S.A. grew its position in shares of USANA Health Sciences, Inc. (NYSE:USNAFree Report) by 13.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 124,008 shares of the company’s stock after purchasing an additional 14,756 shares during the period. Assenagon Asset Management S.A.’s holdings in USANA Health Sciences were worth $4,702,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the company. BOKF NA lifted its stake in USANA Health Sciences by 274.5% in the first quarter. BOKF NA now owns 2,771 shares of the company’s stock worth $133,000 after purchasing an additional 2,031 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of USANA Health Sciences by 9.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock valued at $284,000 after acquiring an additional 494 shares during the last quarter. Exchange Traded Concepts LLC raised its stake in shares of USANA Health Sciences by 4.4% during the third quarter. Exchange Traded Concepts LLC now owns 7,709 shares of the company’s stock valued at $292,000 after acquiring an additional 322 shares during the last quarter. SG Americas Securities LLC bought a new position in shares of USANA Health Sciences during the second quarter valued at about $340,000. Finally, Creative Planning purchased a new position in shares of USANA Health Sciences during the third quarter valued at about $394,000. 54.25% of the stock is currently owned by hedge funds and other institutional investors.

USANA Health Sciences Stock Performance

Shares of USNA opened at $37.30 on Wednesday. The stock has a market cap of $710.64 million, a PE ratio of 13.18, a price-to-earnings-growth ratio of 1.25 and a beta of 0.89. USANA Health Sciences, Inc. has a fifty-two week low of $34.15 and a fifty-two week high of $54.81. The firm’s 50-day simple moving average is $37.81 and its two-hundred day simple moving average is $42.29.

USANA Health Sciences (NYSE:USNAGet Free Report) last announced its quarterly earnings data on Tuesday, October 22nd. The company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.07. The business had revenue of $200.22 million for the quarter, compared to analysts’ expectations of $208.45 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. During the same quarter in the prior year, the company earned $0.59 earnings per share. Equities research analysts predict that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

USNA has been the topic of several research analyst reports. DA Davidson reduced their price target on shares of USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 23rd. StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th.

View Our Latest Research Report on USANA Health Sciences

Insiders Place Their Bets

In other news, Director Gilbert A. Fuller sold 674 shares of the company’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $39.69, for a total value of $26,751.06. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other USANA Health Sciences news, insider Paul A. Jones sold 6,266 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total value of $240,489.08. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Gilbert A. Fuller sold 674 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $39.69, for a total transaction of $26,751.06. The disclosure for this sale can be found here. Corporate insiders own 0.33% of the company’s stock.

USANA Health Sciences Company Profile

(Free Report)

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

Featured Articles

Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences, Inc. (NYSE:USNAFree Report).

Institutional Ownership by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.